Schonfeld Strategic Advisors LLC Bellus Health Inc. Transaction History

Schonfeld Strategic Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$6.46 - $10.02 $1.44 Million - $2.23 Million	-222,956 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$5.56 - $7.99 $523,707 - $752,594	-94,192 Reduced 29.7%	222,956 $1.53 Million
Q4 2021 Feb 14, 2022	BUY	$5.26 - $8.3 $564,803 - $891,229	107,377 Added 51.19%	317,148 $2.55 Million
Q3 2021 Nov 16, 2021	BUY	$2.7 - $6.64 $566,381 - $1.39 Million	209,771 New	209,771 $1.29 Million
Q1 2021 May 17, 2021	SELL	$3.03 - $4.58 $49,692 - $75,112	-16,400 Closed	0 $0

Q4 2020 Feb 16, 2021	BUY	$2.27 - $3.3 $37,228 - $54,120	16,400 New	16,400 $49,000
Q1 2020 May 15, 2020	SELL	$5.77 - $10.85 $936,194 - $1.76 Million	-162,252 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$5.76 - $7.6 $44,352 - $58,520	-7,700 Reduced 4.53%	162,252 $1.23 Million
Q3 2019 Nov 14, 2019	BUY	$6.24 - $8.84 $1.06 Million - $1.5 Million	169,952 New	169,952 $1.09 Million

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.